MEK inhibitors are established therapies in BRAF-driven cancers, yet their broader clinical effect is limited by toxicity, resistance, and modest durability as a monotherapy, particularly in RAS-mutant tumours. Dose intensity is often restricted by severe adve... ...

请注册登录后继续浏览